Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| SUPERNUS PHARM (NASDAQ: SUPN) | Delayed: 28.21 +0.06 (0.21%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.15 | 52 Week High | $26.84 | |||
| Open | $26.81 | 52 Week Low | $9.51 | |||
| Day High | $28.99 | P/E | N/A | |||
| Day Low | $26.74 | EPS | $-2.62 | |||
| Volume | 6,565,162 | |||||
